The special dividend is a pass-through of VYNE's excess cash ahead of the Yarrow merger, not an operating event. The key binary catalyst is the July 16 stockholder vote — rejection would cancel both the dividend and the merger. Monitor vote outcome; post-close, VYNE will be a combined entity focused on Yarrow's pipeline (YB-101 for autoimmune thyroid diseases), shifting the investment thesis entirely.
Price Chart
Executive Summary
VYNE Therapeutics declared a special cash dividend of an estimated $16.5 million ($0.38 per share) in connection with its pending merger with Yarrow Bioscience. The dividend is conditioned upon closing of the merger, which is expected around July 24, 2026, subject to stockholder approval at the July 16 special meeting. This effectively returns VYNE's excess net cash to shareholders as a pre-close distribution.
Key Facts
- Board declared special cash dividend of estimated $16.5 million, or $0.38 per share
- Based on 42,989,506 shares of common stock and common stock equivalents outstanding as of July 9, 2026
- Record date: July 22, 2026; payment to transfer agent on July 23, 2026
- Dividend conditioned upon closing of the merger with Yarrow Bioscience
- Merger closing expected on or about July 24, 2026, subject to stockholder vote at July 16 special meeting
- Merger Agreement originally entered on December 17, 2025
- Dividend represents cash exceeding $0 net cash per Merger Agreement calculation
Financial Impact
Estimated $16.5 million aggregate dividend, representing essentially all of VYNE's net cash returned to stockholders and warrant holders before merger close
Risk Factors
- Stockholders may not approve the merger at the July 16 special meeting, canceling the dividend and the transaction
- Actual dividend amount may be higher or lower than $0.38 per share depending on final net cash calculation
- Pro forma combined entity will be a clinical-stage biotech with no approved products and ongoing capital needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (VYNE) — Batch item 1 | 0001104659-26-082434 |
| Document: tm2620182d2_ex99-1.htm | 0001104659-26-082433 |
| Document: 0001104659-26-082434-index-headers.html | 0001104659-26-082434 |
| Document: 0001104659-26-082434-index.html | 0001104659-26-082434 |
| Document: 0001104659-26-082434.txt | 0001104659-26-082434 |
| 8-K Filing (VYNE) — Batch item 6 | 0001104659-26-082433 |
| Document: tm2620182d1_ex99-1.htm | 0001104659-26-082434 |
| Document: 0001104659-26-082433-index-headers.html | 0001104659-26-082434 |
| Document: 0001104659-26-082433-index.html | 0001104659-26-082434 |
| Document: 0001104659-26-082433.txt | 0001104659-26-082434 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G | — | awaiting T+20 | — | — |
Jul 29, 2026 12w ago | 3 | $28.05 | awaiting T+20 | — | — |
Jul 21, 2026 14w ago | 8-K | $0.8927 | awaiting T+20 | — | — |
Jul 14, 2026 15w ago | 425 / 8-K | $0.7110 | awaiting T+20 | — | — |
Jul 10, 2026 15w ago | 425 / 8-K | $0.6376 | awaiting T+20 | — | — |
Jun 17, 2026 18w ago | EFFECT | $0.6311 $0.7675 | ▲ +21.61% | ▲ +20.30% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers